187 related articles for article (PubMed ID: 35261798)
21. TIC10/ONC201 synergizes with Bcl-2/Bcl-xL inhibition in glioblastoma by suppression of Mcl-1 and its binding partners in vitro and in vivo.
Karpel-Massler G; Bâ M; Shu C; Halatsch ME; Westhoff MA; Bruce JN; Canoll P; Siegelin MD
Oncotarget; 2015 Nov; 6(34):36456-71. PubMed ID: 26474387
[TBL] [Abstract][Full Text] [Related]
22. Preclinical evaluation of the imipridone family, analogs of clinical stage anti-cancer small molecule ONC201, reveals potent anti-cancer effects of ONC212.
Wagner J; Kline CL; Ralff MD; Lev A; Lulla A; Zhou L; Olson GL; Nallaganchu BR; Benes CH; Allen JE; Prabhu VV; Stogniew M; Oster W; El-Deiry WS
Cell Cycle; 2017 Oct; 16(19):1790-1799. PubMed ID: 28489985
[TBL] [Abstract][Full Text] [Related]
23. Novel combination of imipridones and histone deacetylase inhibitors demonstrate cytotoxic effect through integrated stress response in pediatric solid tumors.
Chang WI; Honeyman JN; Zhang J; Lin C; Sharma A; Zhou L; Oliveira J; Tapinos N; Lulla RR; Prabhu VV; El-Deiry WS
Am J Cancer Res; 2023; 13(12):6241-6255. PubMed ID: 38187038
[TBL] [Abstract][Full Text] [Related]
24. Single agent and synergistic combinatorial efficacy of first-in-class small molecule imipridone ONC201 in hematological malignancies.
Prabhu VV; Talekar MK; Lulla AR; Kline CLB; Zhou L; Hall J; Van den Heuvel APJ; Dicker DT; Babar J; Grupp SA; Garnett MJ; McDermott U; Benes CH; Pu JJ; Claxton DF; Khan N; Oster W; Allen JE; El-Deiry WS
Cell Cycle; 2018; 17(4):468-478. PubMed ID: 29157092
[TBL] [Abstract][Full Text] [Related]
25. ONC201 selectively induces apoptosis in cutaneous T-cell lymphoma cells via activating pro-apoptotic integrated stress response and inactivating JAK/STAT and NF-κB pathways.
Ni X; Zhang X; Hu CH; Langridge T; Tarapore RS; Allen JE; Oster W; Duvic M
Oncotarget; 2017 Sep; 8(37):61761-61776. PubMed ID: 28977902
[TBL] [Abstract][Full Text] [Related]
26. Genetic and Pharmacological Screens Converge in Identifying FLIP, BCL2, and IAP Proteins as Key Regulators of Sensitivity to the TRAIL-Inducing Anticancer Agent ONC201/TIC10.
Allen JE; Prabhu VV; Talekar M; van den Heuvel AP; Lim B; Dicker DT; Fritz JL; Beck A; El-Deiry WS
Cancer Res; 2015 Apr; 75(8):1668-74. PubMed ID: 25681273
[TBL] [Abstract][Full Text] [Related]
27. ONC201 kills solid tumor cells by triggering an integrated stress response dependent on ATF4 activation by specific eIF2α kinases.
Kline CL; Van den Heuvel AP; Allen JE; Prabhu VV; Dicker DT; El-Deiry WS
Sci Signal; 2016 Feb; 9(415):ra18. PubMed ID: 26884600
[TBL] [Abstract][Full Text] [Related]
28. Lurbinectedin in small cell lung cancer.
Manzo A; Sforza V; Carillio G; Palumbo G; Montanino A; Sandomenico C; Costanzo R; Esposito G; Laudato F; Mercadante E; La Manna C; Muto P; Totaro G; De Cecio R; Picone C; Piccirillo MC; Pascarella G; Normanno N; Morabito A
Front Oncol; 2022; 12():932105. PubMed ID: 36110944
[TBL] [Abstract][Full Text] [Related]
29. Lurbinectedin as second-line treatment for patients with small-cell lung cancer: a single-arm, open-label, phase 2 basket trial.
Trigo J; Subbiah V; Besse B; Moreno V; López R; Sala MA; Peters S; Ponce S; Fernández C; Alfaro V; Gómez J; Kahatt C; Zeaiter A; Zaman K; Boni V; Arrondeau J; Martínez M; Delord JP; Awada A; Kristeleit R; Olmedo ME; Wannesson L; Valdivia J; Rubio MJ; Anton A; Sarantopoulos J; Chawla SP; Mosquera-Martinez J; D'Arcangelo M; Santoro A; Villalobos VM; Sands J; Paz-Ares L
Lancet Oncol; 2020 May; 21(5):645-654. PubMed ID: 32224306
[TBL] [Abstract][Full Text] [Related]
30. Lurbinectedin: A New Treatment Option for Relapsed/Refractory Small-Cell Lung Cancer.
Shinn LT; Vo KA; Reeves DJ
Ann Pharmacother; 2021 Sep; 55(9):1172-1179. PubMed ID: 33348988
[TBL] [Abstract][Full Text] [Related]
31. Antitumorigenic effect of combination treatment with ONC201 and TRAIL in endometrial cancer
Ray JE; Ralff MD; Jhaveri A; Zhou L; Dicker DT; Ross EA; El-Deiry WS
Cancer Biol Ther; 2021 Dec; 22(10-12):554-563. PubMed ID: 34696710
[TBL] [Abstract][Full Text] [Related]
32. ONC201 Demonstrates Antitumor Effects in Both Triple-Negative and Non-Triple-Negative Breast Cancers through TRAIL-Dependent and TRAIL-Independent Mechanisms.
Ralff MD; Kline CLB; Küçükkase OC; Wagner J; Lim B; Dicker DT; Prabhu VV; Oster W; El-Deiry WS
Mol Cancer Ther; 2017 Jul; 16(7):1290-1298. PubMed ID: 28424227
[TBL] [Abstract][Full Text] [Related]
33. Role of Dopamine Receptors in the Anticancer Activity of ONC201.
Kline CLB; Ralff MD; Lulla AR; Wagner JM; Abbosh PH; Dicker DT; Allen JE; El-Deiry WS
Neoplasia; 2018 Jan; 20(1):80-91. PubMed ID: 29216597
[TBL] [Abstract][Full Text] [Related]
34. Lurbinectedin in small cell lung cancer: real-world experience of a multicentre national early access programme.
Alexander M; Rogers J; Parakh S; Mitchell P; Clay TD; Kao S; Hughes BGM; Itchins M; Kong BY; Pavlakis N; Solomon BJ; John T
Intern Med J; 2024 Feb; ():. PubMed ID: 38369719
[TBL] [Abstract][Full Text] [Related]
35. Oral administration of TRAIL-inducing small molecule ONC201/TIC10 prevents intestinal polyposis in the
Madka V; De La Cruz A; Pathuri G; Panneerselvam J; Zhang Y; Stratton N; Hacking S; Finnberg NK; Safran HP; Sei S; Glaze ER; Shoemaker R; Fox JT; Raufi AG; El-Deiry WS; Rao CV
Am J Cancer Res; 2022; 12(5):2118-2131. PubMed ID: 35693092
[TBL] [Abstract][Full Text] [Related]
36. The preclinical evaluation of TIC10/ONC201 as an anti-pancreatic cancer agent.
Zhang Q; Wang H; Ran L; Zhang Z; Jiang R
Biochem Biophys Res Commun; 2016 Aug; 476(4):260-266. PubMed ID: 27233611
[TBL] [Abstract][Full Text] [Related]
37. ONC201 induces the unfolded protein response (UPR) in high- and low-grade ovarian carcinoma cell lines and leads to cell death regardless of platinum sensitivity.
Rumman M; Buck S; Polin L; Dzinic S; Boerner J; Winer IS
Cancer Med; 2021 May; 10(10):3373-3387. PubMed ID: 33932119
[TBL] [Abstract][Full Text] [Related]
38. ONC201/TIC10 Is Empowered by 2-Deoxyglucose and Causes Metabolic Reprogramming in Medulloblastoma Cells
Dwucet A; Pruss M; Cao Q; Tanriover M; Prabhu VV; Allen JE; Peraud A; Westhoff MA; Siegelin MD; Wirtz CR; Karpel-Massler G
Front Cell Dev Biol; 2021; 9():734699. PubMed ID: 34900991
[TBL] [Abstract][Full Text] [Related]
39. Anti-tumor effects of ONC201 in combination with VEGF-inhibitors significantly impacts colorectal cancer growth and survival in vivo through complementary non-overlapping mechanisms.
Wagner J; Kline CL; Zhou L; Khazak V; El-Deiry WS
J Exp Clin Cancer Res; 2018 Jan; 37(1):11. PubMed ID: 29357916
[TBL] [Abstract][Full Text] [Related]
40. ONC201 Targets AR and AR-V7 Signaling, Reduces PSA, and Synergizes with Everolimus in Prostate Cancer.
Lev A; Lulla AR; Ross BC; Ralff MD; Makhov PB; Dicker DT; El-Deiry WS
Mol Cancer Res; 2018 May; 16(5):754-766. PubMed ID: 29588330
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
